|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Recombinant tyrosinase protein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||Assay Dependent|
|Immunofluorescence (IF)||Assay Dependent|
|Immunohistochemistry (Paraffin) (IHC (P))||2-4 µg/ml|
|Western Blot (WB)||1-2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Miscellaneous PubMed (MISC)||See 2 publications below|
|Immunohistochemistry (IHC)||See 12 publications below|
|ELISA (ELISA)||See 1 publications below|
|Western Blot (WB)||See 3 publications below|
|Immunocytochemistry (ICC)||See 3 publications below|
|Flow Cytometry (Flow)||See 1 publications below|
MA5-14177 targets Tyrosinase in ICC, IF, IHC (P), and WB applications and shows reactivity with Human samples.
The MA5-14177 immunogen is recombinant tyrosinase protein.
Tyrosinase is a copper-containing metalloglycoprotein that catalyzes several steps in the melanin pigment biosynthetic pathway; the hydroxylation of tyrosine to L-3,4-dihydroxy-phenylalanine (dopa), and the subsequent oxidation of dopa to dopaquinone. Mutations of the tyrosinase gene occur in various forms of albinism. Tyrosinase is one of the targets for cytotoxic T-cell recognition in melanoma patients.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
NFATc2 is an intrinsic regulator of melanoma dedifferentiation.
MA5-14177 was used in flow cytometry to identify NFATc2 as a regulator of human melanoma dedifferentiation
|Perotti V,Baldassari P,Molla A,Vegetti C,Bersani I,Maurichi A,Santinami M,Anichini A,Mortarini R||Oncogene (35:2862)||2016|
T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
MA5-14177 was used in immunohistochemistry (paraffin) to investigate T--cell effector function in relation to tumor-escape mechanisms.
|Tjin EP,Konijnenberg D,Krebbers G,Mallo H,Drijfhout JW,Franken KL,van der Horst CM,Bos JD,Nieweg OE,Kroon BB,Haanen JB,Melief CJ,Vyth-Dreese FA,Luiten RM||Clinical cancer research : an official journal of the American Association for Cancer Research (17:5736)||2011|
Malignant perivascular epithelioid cell tumor in children: description of a case and review of the literature.
MA5-14177 was used in immunohistochemistry to report on a case of malignant perivascular epithelioid cell tumor in a child
|Alaggio R,Cecchetto G,Martignoni G,Bisogno G,Cheng L,Sperlì D,d'Amore ES,Dall'Igna P||Journal of pediatric surgery (47:e31)||2012|
Dermoscopic, histological and immunohistochemical evaluation of cancerous features in acquired melanocytic nevi that have been repeatedly exposed to UVA or UVB.
MA5-14177 was used in immunohistochemistry to characterize the cancerous features of acquired melanocytic nevi following repeated exposure to UVA or UVB irradiation
|Manganoni AM,Rossi MT,Sala R,Venturini M,Sereni E,Ungari M,Marocolo D,Lonardi S,Calzavara-Pinton P||Experimental dermatology (21:86)||2012|
Bilateral renal tumors; conventional clear cell carcinoma and contralateral t(6;11)/t(X;17)-like tumor Histomorphologic, immunohistochemical, ultrastructural and molecular genetic studies including the report of a novel mutation in the VHL gene.
MA5-14177 was used in immunohistochemistry to report on a pregnant woman with bilateral renal tumors
|Petersson F,Michal M,Van¿¿ek T,Hora M,Trivunic S,Halbhuber Z,Hes O||Annals of diagnostic pathology (15:362)||2011|
The role of keratinocyte growth factor in melanogenesis: a possible mechanism for the initiation of solar lentigines.
MA5-14177 was used in immunohistochemistry to investigate the role of keratinocyte growth factor in melanogenesis and solar lentigines
|Chen N,Hu Y,Li WH,Eisinger M,Seiberg M,Lin CB||Experimental dermatology (19:865)||2010|
Carcinoid-like pattern in melanoma: report of 4 cases.
MA5-14177 was used in immunohistochemistry to report on four cases of carcinoid-like pattern in melanoma
|Kacerovska D,Michal M,Sosna B,Cempirkova D,Ambrus M,Richtr P,Danis D,Zelger B,Kazakov DV||The American Journal of dermatopathology (31:542)||2009|
Downregulated melanogenic paracrine cytokine linkages in hypopigmented palmoplantar skin.
MA5-14177 was used in immunohistochemistry to investigate the association of ET-1/SCF/receptor linkages with melanocyte function in hypopigmented palmoplantar skin
|Hasegawa J,Goto Y,Murata H,Takata M,Saida T,Imokawa G||Pigment cell and melanoma research (21:687)||2008|
Primitive small cell tumor with epithelial, gangliocytic, neuroendocrine, and mesenchymal differentiation: report of 2 cases.
MA5-14177 was used in immunohistochemistry to report on two cases of a primitive small cell tumor displaying epithelial, gangliocytic, neuroendicrine and mesenchymal differentiation
|Michal M,Kazakov DV,Síma R,Vanecek T||International journal of surgical pathology (15:429)||2007|
Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
MA5-14177 was used in immunohistochemistry to study the therapeutic potential of autologous tumor cells virally transduced with GM-CSF in metastatic melanoma patients
|Luiten RM,Kueter EW,Mooi W,Gallee MP,Rankin EM,Gerritsen WR,Clift SM,Nooijen WJ,Weder P,van de Kasteele WF,Sein J,van den Berk PC,Nieweg OE,Berns AM,Spits H,de Gast GC||Journal of clinical oncology : official journal of the American Society of Clinical Oncology (23:8978)||2005|
Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.
MA5-14177 was used in immunohistochemistry to study the immunogenicity of a unique antigen created by a periredoxin 5 point mutation in human metastatic melanoma
|Sensi M,Nicolini G,Zanon M,Colombo C,Molla A,Bersani I,Lupetti R,Parmiani G,Anichini A||Cancer research (65:632)||2005|
On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients.
MA5-14177 was used in immunohistochemistry to study the role of CD8+ T-cell immunity in disease progression of advanced-stage melanoma
|van Oijen M,Bins A,Elias S,Sein J,Weder P,de Gast G,Mallo H,Gallee M,Van Tinteren H,Schumacher T,Haanen J||Clinical cancer research : an official journal of the American Association for Cancer Research (10:4754)||2004|
Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations.
MA5-14177 was used in immunohistochemistry to study 5 antibodies as diagnostic markers of melanoma incytologic preparation
|Sheffield MV,Yee H,Dorvault CC,Weilbaecher KN,Eltoum IA,Siegal GP,Fisher DE,Chhieng DC||American journal of clinical pathology (118:930)||2002|
Detection of nodal micrometastases using immunohistochemistry and PCR in melanoma of the arm and trunk.
MA5-14177 was used in immunohistochemistry to study nodal micrometastases in patients with arm and trunk melanoma
|Boi S,Cristofolini P,Togni R,Girlando S,Camerani M,Donner D,Cristofolini M,Dalla Palma P||Melanoma research (12:147)||2002|
IL-8 and cathepsin B as melanoma serum biomarkers.
MA5-14177 was used in ELISA to study IL8 and Cathepsin B in the prognosis of melanoma mortality
|Zhang H,Fu T,McGettigan S,Kumar S,Liu S,Speicher D,Schuchter L,Xu X||International journal of molecular sciences (12:1505)||2011|
WIPI1 coordinates melanogenic gene transcription and melanosome formation via TORC1 inhibition.
MA5-14177 was used in western blot to investigate the involvement of WIPI1 in transcriptional regulation of melanogenic gene and melanosome formation
|Ho H,Kapadia R,Al-Tahan S,Ahmad S,Ganesan AK||The Journal of biological chemistry (286:12509)||2011|
Catecholamine effects on human melanoma cells evoked by alpha1-adrenoceptors.
MA5-14177 was used in western blot to study the role of alpha-1-adrenoceptors in the mediating the biological effects of catacholamines in human melanoma cells
|Scarparo AC,Sumida DH,Patrão MT,Avellar MC,Visconti MA,Maria de Lauro Castrucci A||Archives of dermatological research (296:112)||2004|
Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells.
MA5-14177 was used in western blot to study methods for the in vitro induction of cytotoxic T-lymphocytes against allogeneic melanoma cells
|Glazyrin AL,Kan-Mitchell J,Mitchell ML||Cancer immunology, immunotherapy : CII (52:171)||2003|
Establishment of stable cell lines for personalized melanoma cell vaccine.
MA5-14177 was used in immunocytochemistry to establish stable melanoma cell lines for personalized vaccine therapy
|Selvan SR,Carbonell DJ,Fowler AW,Beatty AR,Ravindranath MH,Dillman RO||Melanoma research (20:280)||2010|
Retinal pigment epithelial phenotype induced in human adipose tissue-derived mesenchymal stromal cells.
MA5-14177 was used in immunocytochemistry to study the induction of a retinal pigment epithelial phenotype in human adipose tissue-derived mesenchymal stromal cells
|Vossmerbaeumer U,Ohnesorge S,Kuehl S,Haapalahti M,Kluter H,Jonas JB,Thierse HJ,Bieback K||Cytotherapy (11:177)||2009|
Tyrosinase biosynthesis and trafficking in adult human retinal pigment epithelial cells.
MA5-14177 was used in immunocytochemistry to study the expression and trafficking of tyrosinase in adult human retinal pigment epithelial cells
|Julien S,Kociok N,Kreppel F,Kopitz J,Kochanek S,Biesemeier A,Blitgen-Heinecke P,Heiduschka P,Schraermeyer U||Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fu¿r klinische und experimentelle Ophthalmologie (245:1495)||2007|
Scalable expansion of potent genetically modified human langerhans cells in a closed system for clinical applications.
MA5-14177 was used in flow cytometry to evaluate a novel dendritic cell vaccine strategy
|Yuan J,Kendle R,Ireland J,Heller G,Sadelain M,Young JW,Rivière I||Journal of immunotherapy (Hagerstown, Md. : 1997) (30:634)||2007|